Download PDF
Semin Reprod Med 2001; 19(4): 381-390
DOI: 10.1055/s-2001-18646
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Contraceptive Vaginal Rings

Bryna Harwood1 , Daniel R. Mishell, Jr.2
  • 1Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
  • 2Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, California
Further Information

Publication History

Publication Date:
29 November 2001 (online)

    Permissions and Reprints

ABSTRACT

Contraceptive vaginal rings (CVRs) contain sex steroids that diffuse through a plastic polymer ring at a constant rate and are absorbed directly through the vaginal epithelium into the systemic circulation. This delivery system provides many advantages over oral contraceptives (OCs), including avoidance of the first-pass effect through the liver, constant serum steroid levels, longer duration of use, and greater bioavailability of the hormones. CVRs containing progestin only are designed for continuous use for 3 to 6 months. Those containing progesterone alone are indicated for use in women who are breastfeeding. Large clinical trials of progestin-containing CVRs demonstrated good efficacy and safety of the CVR, with continuation rates similar to that of OCs. CVRs containing a combination of estrogen and progestin are designed to be used for 1 to 12 months in a cyclic manner similar to OCs, with withdrawal bleeding in the fourth week of each cycle. In clinical trials these CVRs have typical use efficacies similar to OCs, with an acceptable pattern of bleeding.

KEYWORD

Contraception - sex steroid hormones - vaginal ring

REFERENCES

  • 1 Macht D. The absorption of drugs and poisons through the vagina.  Journal of Pharmacology Path . 1918;  10 509
    PubMedGoogle Scholar
  • 2 Dzuik P, Cook B. Passage of steroids through silicone rubber.  Endocrinology . 1966;  78 208-211
    PubMedGoogle Scholar
  • 3 Roumen F, Dieben T. Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring.  Contraception . 1999;  59 59-62
    CrossrefPubMedGoogle Scholar
  • 4 Timmer C, Apter D, Voortman G. Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings.  Contraception . 1990;  42 629-642
    CrossrefPubMedGoogle Scholar
  • 5 Landgren B, Johannisson E, Masironi B, Diczfalusy E. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.  Contraception . 1982;  26 567-585
    CrossrefPubMedGoogle Scholar
  • 6 Jackanicz T M. Levonorgestrel and estradiol release from an improved contraceptive vaginal ring.  Contraception . 1981;  24 323-339
    CrossrefPubMedGoogle Scholar
  • 7 Mishell D R, Talas M, Parlow A, Moyer D L. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate.  Am J Obstet Gynecol . 1970;  107 100-107
    PubMedGoogle Scholar
  • 8 World Health Organization. Microdose intravaginal levonorgestrel contraception-a multicentre clinical trial I: contraceptive efficacy and side effects.  Contraception . 1990;  41 105-124
    CrossrefPubMedGoogle Scholar
  • 9 World Health Organization. Microdose intravaginal levonorgestrel contraception-a multicentre clinical trial IV: bleeding patterns.  Contraception . 1990;  41 151-167
    CrossrefPubMedGoogle Scholar
  • 10 Ji G, Hong-zhu S, Gui-ying S, Li-yuan M. Clinical investigation of a low-dose levonorgestrel-releasing vaginal ring.  Fertil Steril . 1986;  46 626-630
    PubMedGoogle Scholar
  • 11 Bounds W, Szarewski A, Lowe D. Preliminary report of unexpected local reactions to a progestogen-releasing contraceptive vaginal ring.  Eur J Obstet Gynecol Reprod Biol . 1993;  48 123-125
    CrossrefPubMedGoogle Scholar
  • 12 Diaz S, Jackanicz T, Herreros C. Fertility regulation in nursing women VIII: progesterone plasma levels and contraceptive efficacy of a progesterone-releasing vaginal ring.  Contraception . 1985;  32 603-621
    PubMedGoogle Scholar
  • 13 Chen J, Wu S, Shao W. The comparative trial of TCu 380A IUD and progesterone-releasing vaginal ring used by lactating women.  Contraception . 1998;  57 371-379
    CrossrefPubMedGoogle Scholar
  • 14 Sivin I, Diaz S, Croxatto H B. Contraceptives for lactating women: a comparative trial of a progesterone-releasing vaginal ring and the copper T 380A IUD.  Contraception . 1997;  55 225-232
    CrossrefPubMedGoogle Scholar
  • 15 Mishell D R, Moore D E, Roy S, Brenner P F, Page M A. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel.  Am J Obstet Gynecol . 1978;  130 55-62
    PubMedGoogle Scholar
  • 16 Sivin I, Mishell D R, Victor A. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings I: use effectiveness.  Contraception . 1981;  24 341-358
    CrossrefPubMedGoogle Scholar
  • 17 Roy S, Krauss R M, Mishell D R, Casagrande J, Pike M C. The effect on lipids and lipoproteins of a contraceptive vaginal ring containing levonorgestrel and estradiol.  Contraception . 1981;  24 429-449
    CrossrefPubMedGoogle Scholar
  • 18 Robertson D, Alvarez F, Sivin I. Lipoprotein patterns in women in Santo Domingo using a levonorgestrel/estradiol contraceptive ring.  Contraception . 1981;  24 469-479
    CrossrefPubMedGoogle Scholar
  • 19 Ahren T, Lithell H, Victor A, Vessby B, Johansson E D. Comparison of the metabolic effects of two hormonal contraceptive methods: an oral formulation and a vaginal ring II: serum lipoproteins and apolipoproteins.  Contraception . 1981;  24 451-467
    CrossrefPubMedGoogle Scholar
  • 20 Ahren T, Lithell H, Victor A, Vessby B, Johansson E D. Comparison of the metabolic effects of two hormonal contraceptive methods-an oral formulation and a vaginal ring I: carbohydrate metabolism and liver function.  Contraception . 1981;  24 415-427
    CrossrefPubMedGoogle Scholar
  • 21 Ahren T, Victor A, Lithell H, Vessby B, Jackanicz T M, Johansson E D. Ovarian function, bleeding control and serum lipoproteins in women using contraceptive vaginal rings releasing five different progestins.  Contraception . 1983;  28 315-327
    CrossrefPubMedGoogle Scholar
  • 22 Adams M, Clarkson T, Koritnik D, Nash H A. Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques.  Fertil Steril . 1987;  47 1010-1018
    PubMedGoogle Scholar
  • 23 Ballagh S A, Mishell D R, Jackanicz T M, Lacarra M, Eggena P. Dose-finding study of a contraceptive ring releasing norethindrone acetate/ethinyl estradiol.  Contraception . 1994;  50 535-549
    CrossrefPubMedGoogle Scholar
  • 24 Ballagh S A, Mishell D R, Lacarra M, Shoupe D, Jackanicz T M, Eggena P. A contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol.  Contraception . 1994;  50 517-533
    CrossrefPubMedGoogle Scholar
  • 25 Weisberg E, Fraser I S, Lacarra M. Efficacy, bleeding patterns, and side effects of a 1-year contraceptive vaginal ring.  Contraception . 1999;  59 311-318
    CrossrefPubMedGoogle Scholar
  • 26 Weisberg E, Fraser I S, Mishell D R, Lacarra M, Darney P, Jackanicz T M. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.  Contraception . 1999;  59 305-310
    CrossrefPubMedGoogle Scholar
  • 27 Weisberg E, Fraser I S, Lacarra M, Mishell D R, Jackanicz T M. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring.  Contraception . 1997;  56 233-239
    CrossrefPubMedGoogle Scholar
  • 28 Laurikka-Routti M, Haukkamaa M, Heikinheimo O. A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry.  Contraception . 1990;  42 111-120
    CrossrefPubMedGoogle Scholar
  • 29 Alvarez-Sanchez F. Evaluation of four different contraceptive vaginal rings: steroid serum levels, luteal activity, bleeding control and lipid profiles.  Contraception . 1992;  46 387-398
    CrossrefPubMedGoogle Scholar
  • 30 Apter D, Cacciatore B, Stenman U, Alapiessa U, Assendorp R. Clinical performance and endocrine profiles of contraceptive vaginal rings releasing 3-keto-desogestrel and ethinylestradiol.  Contraception . 1990;  42 285-295
    CrossrefPubMedGoogle Scholar
  • 31 Olsson S-E, Odlind V. Contraception with a vaginal ring releasing 3-keto desogestrel and ethinylestradiol.  Contraception . 1990;  42 563-572
    CrossrefPubMedGoogle Scholar
  • 32 Timmer C J, Mulders T M. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring.  Clin Pharmacokinet . 2000;  39 233-242
    CrossrefPubMedGoogle Scholar
  • 33 Mulders T M, Dieben T. Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition.  Fertil Steril . 2001;  75 865-870
    CrossrefPubMedGoogle Scholar
  • 34 Roumen F, Apter D, Mulders T M, Dieben T. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl estradiol.  Hum Reprod . 2001;  16 469-475
    CrossrefPubMedGoogle Scholar
  • 35 Fraser I S, Weisberg E, Minehan E, Johansson E D. A detailed analysis of menstrual blood loss in women using Norplant℗ and Nestorone℗ progestogen-only contraceptive implants or vaginal rings.  Contraception . 2000;  61 241-251
    CrossrefPubMedGoogle Scholar
  • 36 World Health Organization. Microdose intravaginal levonorgestrel contraception-a multicentre clinical trial II: expulsions and removals.  Contraception . 1990;  41 125-141
    CrossrefPubMedGoogle Scholar
  • 37 Sivin I, Mishell D R, Victor A. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings II: subjective and objective measures of effects.  Contraception . 1981;  24 359-376
    CrossrefPubMedGoogle Scholar
  • 38 Schwan A, Ahren T, Victor A. Effects of contraceptive vaginal ring treatment on vaginal bacteriology and cytology.  Contraception . 1983;  28 341-347
    CrossrefPubMedGoogle Scholar
  • 39 Roy S, Wilkins J, Mishell D R. The effect of a contraceptive vaginal ring and oral contraceptives on the vaginal flora.  Contraception . 1981;  24 481-491
    CrossrefPubMedGoogle Scholar
  • 40 Fraser I S, Lacarra M, Mishell D R. Vaginal epithelial surface appearances in women using vaginal rings for contraception.  Contraception . 2000;  61 131-138
    CrossrefPubMedGoogle Scholar
  • 41 Faundes A, Hardy E, Reyes Q, Pastene L, Portes-Carrasco R. Acceptability of the contraceptive vaginal ring by rural and urban population in two Latin American countries.  Contraception . 1981;  24 393-414
    CrossrefPubMedGoogle Scholar
  • 42 Fu H, Darroch J E, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth.  Fam Plann Perspect . 1999;  31 56-63
    PubMedGoogle Scholar
      >